CN1277037A - Medicine for treating cardiovascular and cerebrovascular diseases and sexual hypofunction and its preparing process - Google Patents
Medicine for treating cardiovascular and cerebrovascular diseases and sexual hypofunction and its preparing process Download PDFInfo
- Publication number
- CN1277037A CN1277037A CN 00109251 CN00109251A CN1277037A CN 1277037 A CN1277037 A CN 1277037A CN 00109251 CN00109251 CN 00109251 CN 00109251 A CN00109251 A CN 00109251A CN 1277037 A CN1277037 A CN 1277037A
- Authority
- CN
- China
- Prior art keywords
- medicine
- parts
- radix
- semen
- fructus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 64
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 27
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 18
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 17
- 230000001568 sexual effect Effects 0.000 title claims description 6
- 229940079593 drug Drugs 0.000 title description 13
- 238000000034 method Methods 0.000 title description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 11
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 11
- 235000008434 ginseng Nutrition 0.000 claims abstract description 11
- 230000036299 sexual function Effects 0.000 claims abstract 7
- 210000000582 semen Anatomy 0.000 claims description 27
- 241000208340 Araliaceae Species 0.000 claims description 10
- 240000008669 Hedera helix Species 0.000 claims description 10
- 241001057584 Myrrha Species 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 7
- 238000010298 pulverizing process Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000012567 medical material Substances 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 230000005070 ripening Effects 0.000 claims description 3
- 239000002893 slag Substances 0.000 claims description 3
- 241000233948 Typha Species 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 abstract description 3
- 206010003210 Arteriosclerosis Diseases 0.000 abstract description 2
- 206010008025 Cerebellar ataxia Diseases 0.000 abstract description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 abstract description 2
- 206010008132 Cerebral thrombosis Diseases 0.000 abstract description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 abstract description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract description 2
- 208000029078 coronary artery disease Diseases 0.000 abstract description 2
- 208000001297 phlebitis Diseases 0.000 abstract description 2
- 240000008574 Capsicum frutescens Species 0.000 abstract 1
- 235000002568 Capsicum frutescens Nutrition 0.000 abstract 1
- 240000007311 Commiphora myrrha Species 0.000 abstract 1
- 235000006965 Commiphora myrrha Nutrition 0.000 abstract 1
- 235000013175 Crataegus laevigata Nutrition 0.000 abstract 1
- 244000084791 Curculigo orchioides Species 0.000 abstract 1
- 240000007049 Juglans regia Species 0.000 abstract 1
- 235000009496 Juglans regia Nutrition 0.000 abstract 1
- 235000007265 Myrrhis odorata Nutrition 0.000 abstract 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 abstract 1
- 240000002853 Nelumbo nucifera Species 0.000 abstract 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 abstract 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 abstract 1
- 229930195210 Ophiopogon Natural products 0.000 abstract 1
- 244000248557 Ophiopogon japonicus Species 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 240000004371 Panax ginseng Species 0.000 abstract 1
- 244000046095 Psophocarpus tetragonolobus Species 0.000 abstract 1
- 235000010580 Psophocarpus tetragonolobus Nutrition 0.000 abstract 1
- 206010039966 Senile dementia Diseases 0.000 abstract 1
- 244000000231 Sesamum indicum Species 0.000 abstract 1
- 235000003434 Sesamum indicum Nutrition 0.000 abstract 1
- 241000913745 Spatholobus Species 0.000 abstract 1
- 240000000260 Typha latifolia Species 0.000 abstract 1
- 210000003296 saliva Anatomy 0.000 abstract 1
- 235000020234 walnut Nutrition 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 206010020772 Hypertension Diseases 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 206010019468 Hemiplegia Diseases 0.000 description 4
- 210000004958 brain cell Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000004913 activation Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 208000024806 Brain atrophy Diseases 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 208000001435 Thromboembolism Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- CAKJEGSGMRHDLS-UHFFFAOYSA-N [K].[Cr].[Cr] Chemical compound [K].[Cr].[Cr] CAKJEGSGMRHDLS-UHFFFAOYSA-N 0.000 description 1
- PGTXKIZLOWULDJ-UHFFFAOYSA-N [Mg].[Zn] Chemical compound [Mg].[Zn] PGTXKIZLOWULDJ-UHFFFAOYSA-N 0.000 description 1
- QGIUMAYQVOGGBI-UHFFFAOYSA-N [P].[Ca].[Se] Chemical compound [P].[Ca].[Se] QGIUMAYQVOGGBI-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 description 1
- 229960003099 amcinonide Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- -1 flavone compound Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 229940126532 prescription medicine Drugs 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a medicament for treating cardiovascular and cerebrovascular diseases and sexual function, which is prepared from ginseng, ophiopogon root, root of red rooted saliva, red peony root, curculigo orchioides, lotus rhizome node, myrrh, cattail pollen, sesame, malt, spatholobus stem, hyacinth bean, haw, walnut kernel and hot pepper, and can be used for treating coronary heart disease, cerebral thrombosis, cerebral hemorrhage, angiitis, phlebitis, arteriosclerosis, cerebellar ataxia, senility and climacteric syndrome.
Description
The present invention relates to a kind of medicine for the treatment of cardiovascular and cerebrovascular disease and sexual hypofunction, specific description is that Chinese herbal medicine is the main Chinese patent medicine of forming, the invention still further relates to its preparation method, can be used for treating phlebitis, vasculitis, aging, climacteric syndrome, cerebellar ataxia that arteriosclerosis, hypertension, coronary heart disease, angina pectoris, myocardial infarction, cerebral thrombosis, cerebral hemorrhage, cerebral embolism, cerebral infarction sequela, sexual hypofunction, impotence and premature ejaculation, limbs thromboembolism worn with age, that sclerosis of blood vessels causes cause.
Cardiovascular and cerebrovascular disease is the Senile disease of harm humans health, serious consequence is the mortality rate height, the disability rate height, cause life and financial burden for family and society, the treatment cardiovascular and cerebrovascular disease is a problem that urgency is to be furtherd investigate at present, the sequela that stays for the cardiovascular and cerebrovascular disease acute stage particularly, medical circle needs the technical barrier that solves fast especially.
Both at home and abroad for the medicine of cardiovascular and cerebrovascular disease, following several shortcoming is arranged at present:
1, amcinonide easily causes organism endocrine disorder, edema etc.
2, the anticoagulant medicine causes bleeding easily, and is not all effective to any thrombosis.
3, platelet suppressant drug is only effective to slight thrombosis.
4, the calcium ion antagonist blood pressure lowering is not lasting.
5, the curative effect of medication of free radical resisting is slight.
6, cerebral metabolism activator can only reduce the degree that disables.
More than these medicines also need clinical proportioning, treatment procedure is cumbersome, and all is some chemicals, toxic side effect, untoward reaction, contraindication.
The characteristics that pharmaceutical preparation of the present invention is better than said medicine are exactly the many usefulness of a medicine, can be used for hemorrhagic and ischemic cardiovascular and cerebrovascular disease, can be used as the wide spectrum medicine for treating thrombus.Though the Chinese medicine preparation of a lot of treatment cardiovascular and cerebrovascular disease is arranged,, does not stay sequela after the advantage of medicine of the present invention is cured exactly can all leave deformity in various degree after treating.
The purpose of this invention is to provide a kind of hypoglycemic, improve hypercoagulability, dredge microcirculation, enhancing human body immunity, get through and stop up cardiovascular and cerebrovascular vessel, activation brain cell, recovery function of nervous system, the i.e. pure Chinese herbal and crude drugs preparations of a kind of easily again wide spectrum thromboembolism preventing of economy.
The preparation method that the purpose of this invention is to provide this cardiovascular disease therapies agent.
Solution of the present invention is the theory according to the combination of Chinese and Western medicine, understanding and Therapeutic Principle to disease, achieve with reference to modern pharmacological research, from Chinese medicine, pick out have the replenishing QI and blood qualcomm meridian, the homologous vegetable Chinese herbal medicine of medicated diet that nourishing the liver and kidney, beneficial essence add marrow, by the theory of Chinese medical science prescription, skimming the cream off milk makes its performance eliminate cerebral edema, promotion brain cell metabolism activation, reduce cell injury, repair brain cell, prevent the lipoprotein decomposition, promote carbohydrate metabolism, disperse blood stasis and dredge collateral, makes cardiovascular and cerebrovascular vessel recover the effect of function of nervous system.
Medicine of the present invention is formed (consumption is a weight portion) by following component
Radix Ginseng 3-5 part Nodus Nelumbinis Rhizomatis 50-70 part Caulis Spatholobi 35-45 part
Radix Ophiopogonis 50-70 part Myrrha 20-30 part Semen Lablab Album 20-30 part
Radix Salviae Miltiorrhizae 100-120 part Pollen Typhae 20-30 part Fructus Crataegi dry slice 40-50 part
Radix Paeoniae Rubra 30-50 part Semen Sesami 30-40 part Semen Juglandis 30-35 part
Rhizoma Curculiginis 10-20 part Fructus Hordei Germinatus 20-30 part is fried Fructus Capsici 5-10 part
Preparing medicine optimum ratio weight range of the present invention is:
Radix Ginseng 2-4 part Nodus Nelumbinis Rhizomatis 40-60 part Caulis Spatholobi 30-40 part
Radix Ophiopogonis 40-60 part Myrrha 15-20 part Semen Lablab Album 20-25 part
Radix Salviae Miltiorrhizae 90-100 part Pollen Typhae 15-20 part Fructus Crataegi dry slice 30-40 part
Radix Paeoniae Rubra 25-40 part Semen Sesami 30-35 part Semen Juglandis 25-30 part
Rhizoma Curculiginis 10-15 part Fructus Hordei Germinatus 20-25 part is fried Fructus Capsici 5-8 part
Medicine optimum weight proportioning of the present invention is:
60 parts of 50 portions of Caulis Spatholobis of 3 parts of Nodus Nelumbinis Rhizomatis of Radix Ginseng 30 parts of Radix Ophiopogonis
20 parts of 90 parts of Pollen Typhaes of 20 parts of Radix Salviae Miltiorrhizaes of 25 portions of Semen Lablab Albums of Myrrha
35 parts of 35 parts of Semen Juglandiss of 35 portions of Semen Sesamis of 50 parts of Radix Paeoniae Rubra of Fructus Crataegi dry slice
15 parts of Fructus Hordei Germinatus of Rhizoma Curculiginis are fried 5 parts in Fructus Capsici for 30 parts
Above-mentioned each component is made medicine production method of the present invention is:
1, earlier that Fructus Capsici is air-dry, fry into the blackout color and cross 120 mesh sieves.
2, Radix Ginseng, Semen Juglandis, Seem Lablab Album, Pollen Typhae, Semen Sesami, Radix Ophiopogonis, Myrrha are pulverized 120 order fineness.
3, getting Radix Salviae Miltiorrhizae Radix Paeoniae Rubra, Rhizoma Curculiginis, Nodus Nelumbinis Rhizomatis, Fructus Hordei Germinatus, Caulis Spatholobi, Fructus Crataegi dry slice washes and adds 300 degrees centigrade of decoctions of 10 times of water gagings surplus 200 gram extracts of every kilogram of medical material of back simmer down to that remove slag.
4, with medicine juice with after medicated powder mixes, air-dry pulverizing 120 order fineness, tablet or powder (powder promptly is electuary) are made in ripening sterilization 30 minutes.
5, also 200 degrees centigrade of decoctings of this prescription medicine can be boiled every kilogram and make 2 kilograms of medicinal liquids and add 1 kilogram of yellow wine, make oral liquid, after filtration precipitation, autoclaving, bottling.
An important feature of the present invention is exactly to contain abundant nutrition in the medicament, and wherein vegetable protein is rich in 16 seed amino acids up to 10%, is to strengthen vagus nerve to supply with adjust blood pressure, enhancing cell humoral immunization, the indispensable material of nutrient vessel.
Various amino acid profiles contain scale in the medicine of the present invention:
| Title | Content (mg/100g) | Title | Content (mg/100g) | Title | Content (mg/100g) |
| Threonine | 412.8 | Aspartic acid | 210.2 | Alanine | 851.2 |
| Glutamic acid | 454.6 | Phenylalanine | 607.9 | Glycine | 356.2 |
| Arginine | 643.3 | Isoleucine | 539.6 | Serine | 508.6 |
| Histidine | 202.4 | Valine | 788.9 | Tryptophan | 210.1 |
| Leucine | 1015.0 | Tyrosine | 340.5 | ||
| Lysine | 434.2 | Proline | 490.0 |
To be rich in potassium, magnesium, phosphorus, ferrum, calcium, selenium and other trace elements in the combination agent of the present invention be to endocrine adjusting and strengthen the indispensable material of hematopoietic function, each chemical element content such as following table in the medicine of the present invention:
| Title | Content (mg/100g) | Title | Content (mg/100g) | Title | Content (mg/100g) |
| Potassium chromium chromium | ??835.2 ??169.6 | Zinc-magnesium | ??19.8 ??1510 | The selenium phosphorus calcium | ????0.15 ????321.2 ????1320 |
Another important feature is to contain abundant vitamin E, C, A multiple nutrients material in the medicament among the present invention, and the brain cell of promotion metabolism activation is arranged, and reduces and organizes oxygen consumption to remove free radical enhancing tissue to anoxybiotic toleration; The water-soluble fibre cellulose content reaches 7-25% and can promote gastrointestinal emptying in the medicament of the present invention, reduce the absorption of glycolipid fat, contain abundant choline material and flavone compound in this medicament, content be 1.5-3.1% can blood fat reducing, fall blood sticking, promote microcirculation, increase the heart and brain blood perfusion, the logical again and side that helps cardiovascular and cerebrovascular vessel is propped up circulation foundation, medicament clinical trial of the present invention has following advantage:
1, prescription of the present invention is compatible with natural food medicine and natural medical Chinese crude drug, utilize the comprehensive function of each herbal medicine, the treatment cardiovascular and cerebrovascular disease, also can treat the diabetes close with cardiovascular and cerebrovascular vessel, the blood fat reducing of energy blood sugar lowering, worn with age, the sexual hypofunction that sclerosis of blood vessels causes, aging, climacteric syndrome etc.
Medicine of the present invention is nutritious, and no bitterness, sour and sweet palatability, no chemical addition agent, nontoxic conform to national pharmaceutical control law and food hygiene law.
Medicine of the present invention has no side effect, has no adverse reaction, does not have contraindication.
The characteristics of medicine of the present invention are that plant nutrient medicine and drug for invigorating blood circulation and eliminating stasis are compatible and be equipped with hemostasis and do not stay the stasis of blood, blood stasis dispelling and not hemorrhage medicine, can be used for all types of cardiovascular and cerebrovascular diseases, broken through the single shortcoming of curative effect of medicine, is a kind of wide spectrum medicine for treating thrombus of pure Chinese medicinal preparation.Characteristics of the present invention are that the treatment cardiovascular and cerebrovascular disease does not stay sequela, also can treat old angiopathy sequela patient, reach the hypothyroid disease of therapeutic by the treatment cardiovascular and cerebrovascular disease, balancing blood pressure, curative effect is lasting, can be used for hypertension and hypotensive treatment, solved the difficult problem that hypertension relies on medicine for a long time, desirable what a kind of medicine for the treatment of cerebrovascular of acting as.
The effect that medicine of the present invention is treated cardiovascular and cerebrovascular vessel: apoplexy sequela paralysis, hemiplegia, brain atrophy, take that thrombolytic glue is assisted, brain ruton, network be glad logical etc., all not having positive effect took medicine 1-3 of the present invention month, paralysis can be taken care of oneself, hemiplegia recovers normal, and brain atrophy, mental retardation recovery extent are more than 90%.Early stage with medicine treatment cardiovascular and cerebrovascular vessel thrombosis of the present invention, treated one month, do not stay any sequela.
For showing that the present invention treats hypertensive curative effect, observe through clinical 50 examples, select medical history, the state of an illness, age, sex, and 50 suitable routine matched groups of former Therapeutic Method, stipulated adult hyperpietic man 20 examples that hypertensive diagnostic criteria is made a definite diagnosis in 1978 according to World Health Organization (WHO), woman's 30 examples, age 40 is to 75 years old, and course of disease half a year to 30 year, blood pressure is more than 180/100 millimetres of mercury, test group is inactive depressor on former treatment basis, obey medicine of the present invention, matched group is blood pressure lowering routinely, treats two months, instructions of taking: each 0.5g, day obeys 3 times, and boiled water is taken after mixing it with water, clinical test results such as following table:
Table one: mm mercury column
For showing the curative effect of Drug therapy cerebrovascular of the present invention, clinically select case 35 people, take medicine of the present invention, it is glad logical that matched group 30 people take network, took simultaneously two months, and curative effect shows as a result:
Table 2: medicine of the present invention is obeyed 3 times every day, each 0.5g
| Case load | Network is glad logical | Medicine of the present invention | |||
| Before | After | Before | After | ||
| Test group | ????35 | Paralysis facial hemiparalysis hemiplegia | Recovering orthobiosis takes care of oneself | ||
| Matched group | ????30 | The hemiplegia myasthenia of limbs | Do not have obviously and improve | ||
The effect of blood fat reducing of the present invention shows: test group 60 people take the each 0.5g of medicine of the present invention and serve on 2 months every days 3 times, and matched group 60 people took Elasterin 3 months.
Table 3: medicine of the present invention and the average concentration change of Elasterin contrast blood fat:
| Case | The Elasterin consumption | Serum cholesterol meansigma methods mmoL/L | Serum levels of triglyceride meansigma methods mmoL/L | ||||
| Before | After | Before | After | Before | After | ||
| Test group contrast level | ?60 ?60 | ????0 ?400mg | ????0 ?400mg | ?5.73±1.10 ?5.67±1.06 | ?4.50±0.70 ?5.10±0.99 | ?2.14±1.09 ?2.09±0.91 | ?1.20±0.55 ?2.02±0.30 |
Test shows that pharmaceutical treatment hypertension, hyperlipemia of the present invention, the cerebral infarction person that obtains the significant curative effect accounts for 100% cure rate and accounts for 95/100.
Embodiment:
Take by weighing raw material by following proportioning:
Radix Ginseng: 3 kilograms; 50 kilograms of Nodus Nelumbinis Rhizomatis; Caulis Spatholobi: 30 kilograms; Radix Ophiopogonis: 60 kilograms; Myrrha: 25 kilograms; Semen Lablab Album: 20 kilograms; Radix Salviae Miltiorrhizae: 90 kilograms; Pollen Typhae: 20 kilograms; Fructus Crataegi dry slice: 50 kilograms; Radix Paeoniae Rubra: 35 kilograms; Semen Sesami: 35 kilograms; Semen Juglandis: 35 kilograms; Rhizoma Curculiginis: 15 kilograms; Fructus Hordei Germinatus: 30 kilograms; Fry Fructus Capsici: 5 kilograms.
Production method is as follows:
1, earlier the air-dry stir-fry blackout of Fructus Capsici is pulverized 120 order fineness;
2, with Radix Ginseng, Semen Juglandis, Seem Lablab Album, Pollen Typhae, Semen Sesami, Radix Ophiopogonis, Myrrha, pulverizing 120 order fineness;
3, get Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Rhizoma Curculiginis, Nodus Nelumbinis Rhizomatis, Fructus Hordei Germinatus, Caulis Spatholobi, Fructus Crataegi dry slice and clean, add 300 degrees centigrade of decoctions of 10 times of water gagings, after removing slag, the surplus 200 gram extracts of every kilogram of medical material of simmer down to;
4, with medicine juice with after medicated powder mixes, air-dry pulverizing 120 order fineness, tablet or powder are made in ripening sterilization 30 minutes;
5, also the medicinal 200 degrees centigrade of decoctings of the present invention can be boiled, every kilogram of medical material is made 2 kilograms of medicinal liquids, adds 1 kilogram of yellow wine, makes oral liquid, after filtration, precipitation, high pressure, sterilization, bottling.
Each oral 05 gram of powder tablet, oral liquid are obeyed 50 milliliters of every days 3 times at every turn.
Claims (7)
1, a kind of medicine for the treatment of cardiovascular and cerebrovascular disease and sexual hypofunction is characterized in that it is the medicament of being made by the raw material of following weight ratio.
Radix Ginseng 3-5 part Nodus Nelumbinis Rhizomatis 50-70 part Caulis Spatholobi 35-45 part
Radix Ophiopogonis 50-70 part Myrrha 20-30 part Semen Lablab Album 20-30 part
Radix Salviae Miltiorrhizae 100-120 part Pollen Typhae 20-30 part Fructus Crataegi dry slice 40-50 part
Radix Paeoniae Rubra 30-50 part Semen Sesami 30-40 part Semen Juglandis 30-35 part
Rhizoma Curculiginis 10-20 part Fructus Hordei Germinatus 20-30 part is fried Fructus Capsici 5-10 part
2, according to the medicine of described treatment cardiovascular and cerebrovascular vessel of claim 1 and sexual function, wherein each proportion of raw materials is:
Radix Ginseng 2-4 part Nodus Nelumbinis Rhizomatis 40-60 part Caulis Spatholobi 30-40 part
Radix Ophiopogonis 40-60 part Myrrha 15-20 part Semen Lablab Album 20-25 part
Radix Salviae Miltiorrhizae 90-100 part Pollen Typhae 15-20 part Fructus Crataegi dry slice 30-40 part
Radix Paeoniae Rubra 25-40 part Semen Sesami 30-35 part Semen Juglandis 25-30 part
Rhizoma Curculiginis 10-15 part Fructus Hordei Germinatus 20-25 part is fried Fructus Capsici 5-8 part
3, the medicine of treatment cardiovascular and cerebrovascular vessel according to claim 1 and sexual function, wherein the weight proportion of middle raw material is:
30 parts of 50 portions of Caulis Spatholobis of 3 parts of Nodus Nelumbinis Rhizomatis of Radix Ginseng
20 parts of 25 portions of Semen Lablab Albums of 60 parts of Myrrhas Radix Ophiopogonis
50 parts of 20 parts of Fructus Crataegi dry slice of 90 parts of Pollen Typhaes of Radix Salviae Miltiorrhizae
35 parts of 35 portions of Semen Juglandis of 35 portions of Semen Sesamis of Radix Paeoniae Rubra
15 parts of Fructus Hordei Germinatus of Rhizoma Curculiginis are fried 5 parts in Fructus Capsici for 30 parts
4,, it is characterized in that said medicament is a said dosage form on any pharmaceutics according to the medicine of claim 1,2,3 described treatment cardiovascular and cerebrovascular disease and sexual function.
5,, it is characterized in that said medicament is arranged is powder, tablet or decoction according to the medicine of described treatment cardiovascular of claim 4 and sexual function.
6, according to the medicine of described treatment cardiovascular and cerebrovascular vessel of claim 5 and sexual function, it is characterized in that getting earlier Fructus Capsici air-dry, fry black 120 orders of pulverizing, get Semen Juglandis Radix Ginseng, Seem Lablab Album, Pollen Typhae, Semen Sesami, Radix Ophiopogonis, Myrrha, pulverizing 120 orders, getting Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Rhizoma Curculiginis, Nodus Nelumbinis Rhizomatis, Fructus Hordei Germinatus, Caulis Spatholobi, Fructus Crataegi dry slice again washes, add 300 degrees centigrade of decoctions of 10 times of water gagings, the back of removing slag concentrates the surplus 200g extract of every kilogram of medical material, with medicine juice mix with medicated powder, air-dry, pulverize 120 orders, tablet or powder were made in the ripening sterilization in 30 minutes.
7, according to the medicine of described treatment cardiovascular and cerebrovascular vessel of claim 5 and sexual function, it is characterized in that 200 degrees centigrade of decoctings of medicine of the present invention are boiled, make 2 kilograms of medicinal liquids for every kilogram, add 1 kilogram of yellow wine, make oral liquid, after filtration, the precipitation, the bottling.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00109251 CN1277037A (en) | 2000-06-20 | 2000-06-20 | Medicine for treating cardiovascular and cerebrovascular diseases and sexual hypofunction and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00109251 CN1277037A (en) | 2000-06-20 | 2000-06-20 | Medicine for treating cardiovascular and cerebrovascular diseases and sexual hypofunction and its preparing process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1277037A true CN1277037A (en) | 2000-12-20 |
Family
ID=4579531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 00109251 Pending CN1277037A (en) | 2000-06-20 | 2000-06-20 | Medicine for treating cardiovascular and cerebrovascular diseases and sexual hypofunction and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1277037A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101043898B (en) * | 2004-10-01 | 2012-12-12 | 索法股份公司 | Use of winter savory or its extract for preparing a medicament for the treatment of premature ejaculation |
-
2000
- 2000-06-20 CN CN 00109251 patent/CN1277037A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101043898B (en) * | 2004-10-01 | 2012-12-12 | 索法股份公司 | Use of winter savory or its extract for preparing a medicament for the treatment of premature ejaculation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1051237C (en) | Meicinal prepn. "Kexianling" for curing epilepsy | |
| CN1107359A (en) | Galenic composition | |
| CN1939506A (en) | Vision-improving preparation with depressor, blood-sugar and blood-fat lowering functions and its making method | |
| CN1879802A (en) | Nutritious Chinese medicinal product for replenishing liver and kidney, resisting senility, decreasing blood fat, blood sugar and blood pressure and method for preparing same | |
| CN1478508A (en) | Chinese medicinal composition for treating fatty liver and its preparation method | |
| CN1232279C (en) | Antilipemic Chinese medicine | |
| CN1277037A (en) | Medicine for treating cardiovascular and cerebrovascular diseases and sexual hypofunction and its preparing process | |
| CN1063649C (en) | Red ginseng and hawthorn fruit health-care wine | |
| CN1045892C (en) | Chinese medicine Guanxintong for preventing and curing coronary heart disease and angina pectoris, and producing process thereof | |
| CN1853702A (en) | Chinese medicinal preparation for lowering blood sugar, blood fat and blood pressure, improving blood flow and immune and its making method | |
| CN1799582A (en) | Blood sugar- and blood pressure-lowering medicine | |
| CN1272054C (en) | Medicine for treating diabetes and its preparing process | |
| CN1899385A (en) | Process for preparing Chinese medicine compound injection for treating chronic renal failure and use | |
| CN1251751C (en) | Chinese traditional medicine for treating chronic liver disease and anti hepatic fibrosis | |
| CN1245197C (en) | Chinese medicine preparation for treating coronary heart disease and viral myocarditis | |
| CN1201811C (en) | Chinese medicine composition for treating myopia and preparing method thereof | |
| CN100340232C (en) | Jinshu leaf styptic mixture and its preparing method and use | |
| CN1850265A (en) | Chinese medicine for treating nephrosis Yang deficiency syndrome | |
| CN108578578A (en) | A kind of pharmaceutical composition and preparation method thereof | |
| CN1263490C (en) | Yang reinforcing medicine and its preparation method | |
| CN1279961C (en) | Chinese prepared drug formulation for stopping cough and eliminating sputum and its preparation process | |
| CN1857599A (en) | Medicine for lowering blood sugar, blood fat and blood pressure, raising blood flow rate and raising immunity and its preparing method | |
| CN1274353C (en) | Medication for curing children's infantile malnutrition and preparation method | |
| CN1063077C (en) | Traditional Chinese medicine composition for lowering blood-lipid, and method for preparing same | |
| CN1063074C (en) | Chinese herbs injection for treating oncoma (cancer) and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |